FLUIDIGM CORPORATION (NASDAQ:FLDM) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition |
On January9, 2017, Fluidigm Corporation issued a press release
announcing preliminary fourth quarter and full year 2016 revenue.
A copy of the press release is furnished herewith as Exhibit
99.1.
Item7.01. |
Regulation FD Disclosure. |
The Company is updating its investor presentation information as
set forth in Exhibit 99.2, which is attached hereto and
incorporated herein by reference.
Item9.01 |
Financial Statements and Exhibits |
(d) Exhibits.
|
|
Description | |
| 99.1 | Fluidigm Corporation Press Release dated January9, 2017 | |
| 99.2 |
Fluidigm Corporation Investor Presentation dated January9, 2017 |
The information furnished in this Current Report under Item2.02
and the exhibit attached hereto shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
About FLUIDIGM CORPORATION (NASDAQ:FLDM)
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers. FLUIDIGM CORPORATION (NASDAQ:FLDM) Recent Trading Information
FLUIDIGM CORPORATION (NASDAQ:FLDM) closed its last trading session up +0.28 at 8.33 with 404,259 shares trading hands.